Phase II study of liarozole in advanced non-small cell lung cancer
O'Byrne, Kenneth J., Han, C., Mitchell, K., Lane, D., Carmichael, J., Harris, A. L., & Talbot, D. C. (1998) Phase II study of liarozole in advanced non-small cell lung cancer. European Journal of Cancer, 34(9), pp. 1463-1466.
The aim of this phase II study was to investigate the efficacy and tolerability of liarozole, a novel benzimidazole derivative, in non-small cell lung cancer (NSCLC). Liarozole 300 mg twice daily orally was evaluated in 14 patients with stage IIIB and IV NSCLC. 8 patients had received prior treatment with chemotherapy and/or radiotheraphy. WHO toxocity grading and response criteria were used. Liarozole was well tolerated. Grade 2 toxicities included alopecia (1 patient), dermatological toxicity (5 patients), dry mouth (2 patients) and nausea and vomiting (2 patients). Leukocytosis was seen in 5 patients, including 2 cases with an elevated white cell count pretreatment. Liarozole was discontinued in 1 patient who developed intolerable progressive pruritis associated with an erythematous rash. No objective tumour response was seen, all 14 patients developing progressive disease with 4 months of commencing treatment. Liarozole was well tolerated but was ineffective as single as single agent therapy in the management of NSCLC. The side-effect profile was compatible with inhibition of retinoic acid degradation.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Angiogenesis, Liarozole, Non-small cell lung cancer, Retinoids, benzimidazole derivative, adult, advanced cancer, aged, alopecia, antineoplastic activity, article, cancer chemotherapy, clinical article, clinical trial, drug efficacy, drug tolerance, female, human, leukocytosis, lung non small cell cancer, male, nausea, oral drug administration, phase 2 clinical trial, priority journal, pruritus, skin toxicity, vomiting, xerostomia, Administration, Oral, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Imidazoles, Lung Neoplasms, Middle Aged, Treatment Outcome|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 1998 Pergamon|
|Deposited On:||11 Dec 2013 02:12|
|Last Modified:||11 Dec 2013 02:12|
Repository Staff Only: item control page